BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11235953)

  • 1. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.
    Yamanaka R; Zullo SA; Tanaka R; Blaese M; Xanthopoulos KG
    J Neurosurg; 2001 Mar; 94(3):474-81. PubMed ID: 11235953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.
    Yamanaka R; Zullo SA; Ramsey J; Yajima N; Tsuchiya N; Tanaka R; Blaese M; Xanthopoulos KG
    J Neurosurg; 2002 Sep; 97(3):611-8. PubMed ID: 12296646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA.
    Yamanaka R; Yajima N; Tsuchiya N; Honma J; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG
    J Neurosurg; 2002 Nov; 97(5):1184-90. PubMed ID: 12450042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12.
    Yamanaka R; Zullo SA; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG
    Neurosurg Focus; 2000 Dec; 9(6):e7. PubMed ID: 16817690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12.
    Yamanaka R; Tsuchiya N; Yajima N; Honma J; Hasegawa H; Tanaka R; Ramsey J; Blaese RM; Xanthopoulos KG
    J Neurosurg; 2003 Oct; 99(4):746-53. PubMed ID: 14567611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus.
    Yamanaka R; Zullo SA; Ramsey J; Onodera M; Tanaka R; Blaese M; Xanthopoulos KG
    Cancer Gene Ther; 2001 Oct; 8(10):796-802. PubMed ID: 11687903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.
    Zhu X; Lu C; Xiao B; Qiao J; Sun Y
    J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.
    Määttä AM; Liimatainen T; Wahlfors T; Wirth T; Vähä-Koskela M; Jansson L; Valonen P; Häkkinen K; Rautsi O; Pellinen R; Mäkinen K; Hakumäki J; Hinkkanen A; Wahlfors J
    Int J Cancer; 2007 Aug; 121(4):863-70. PubMed ID: 17443493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
    Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
    Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine therapy with dendritic cells transfected with Il13ra2 mRNA for glioma in mice.
    Saka M; Amano T; Kajiwara K; Yoshikawa K; Ideguchi M; Nomura S; Fujisawa H; Kato S; Fujii M; Ueno K; Hinoda Y; Suzuki M
    J Neurosurg; 2010 Aug; 113(2):270-9. PubMed ID: 19895199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma.
    Saito R; Mizuno M; Nakahara N; Tsuno T; Kumabe T; Yoshimoto T; Yoshida J
    Int J Cancer; 2004 Sep; 111(5):777-82. PubMed ID: 15252850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.
    Kim CH; Hong MJ; Park SD; Kim CK; Park MY; Sohn HJ; Cho HI; Kim TG; Hong YK
    Cancer Immunol Immunother; 2006 Nov; 55(11):1309-19. PubMed ID: 16463038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.
    Melero I; Quetglas JI; Reboredo M; Dubrot J; Rodriguez-Madoz JR; Mancheño U; Casales E; Riezu-Boj JI; Ruiz-Guillen M; Ochoa MC; Sanmamed MF; Thieblemont N; Smerdou C; Hervas-Stubbs S
    Cancer Res; 2015 Feb; 75(3):497-507. PubMed ID: 25527611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
    Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
    Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma.
    Jiang XB; Lu XL; Hu P; Liu RE
    Vaccine; 2009 Oct; 27(44):6210-6. PubMed ID: 19699331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer therapy using a self-replicating RNA vaccine.
    Ying H; Zaks TZ; Wang RF; Irvine KR; Kammula US; Marincola FM; Leitner WW; Restifo NP
    Nat Med; 1999 Jul; 5(7):823-7. PubMed ID: 10395329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography.
    Asselin-Paturel C; Lassau N; Guinebretière JM; Zhang J; Gay F; Bex F; Hallez S; Leclere J; Peronneau P; Mami-Chouaib F; Chouaib S
    Gene Ther; 1999 Apr; 6(4):606-15. PubMed ID: 10476220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.